Latest news with #TriClip
Hindustan Times
4 days ago
- Health
- Hindustan Times
Cardiologists says he wishes more people knew how to 'avoid open heart surgery': No chest cutting, bypass machine needed
Dr Dmitry Yaranov, a cardiologist known as 'Heart Transplant Doc' on Instagram, took to the platform on August 9 to share a post in which he said, 'Being a cardiologist for years, I wish more people knew they could avoid open-heart surgery.' In his post, the doctor explained how mitral and tricuspid valves are crucial in maintaining blood flow in the right direction. Also read | Minimally invasive cardiac surgery: Heart risks for your parents, benefits, lifestyle changes, recovery secrets The cardiologist explained how minimally invasive procedures like MitraClip and TriClip offer promising solutions for patients with leaky heart valves. (Representative image) He said, 'We used to crack open the chest to fix a leaky heart valve. Now? We clip it — through a vein. Let's talk mitral and tricuspid valves — the heart's inlet valves, constantly working to keep blood flowing in the right direction. But when they leak — called regurgitation — blood flows backward, and the heart starts to fail.' What are MitraClip and TriClip? When these valves leak, it can lead to serious complications, but fortunately, advancements in medical technology have introduced minimally invasive procedures to address these issues, Dr Yaranov highlighted. He said, 'Old-school fix? Open-heart surgery. Not everyone could handle it. Today? We've flipped the script. With devices like MitraClip (for mitral) and TriClip (for tricuspid), we can fix the valve without surgery.' MitraClip is a device used to treat mitral regurgitation, a condition where the mitral valve leaks, allowing blood to flow backward. The MitraClip is inserted through a vein in the leg and clips the valve's leaflets together to reduce leakage. TriClip, a similar device designed for the tricuspid valve, also clips the leaflets together to minimise regurgitation. The TriClip is specifically made for the tricuspid valve and has shown promising results in reducing symptoms and hospitalisations for heart failure. 'Small clip, big impact' Explaining these, Dr Yaranov said, 'Just a catheter through a vein in the leg. No chest cutting. No bypass machine. Just a tiny clip, placed right on the valve. It brings the leaflets together, reduces the leak, and the patient usually goes home the next day. Mitral regurgitation is the most common valve disease in the US. And tricuspid used to be ignored — but not anymore. We're now treating patients who were once told 'there's nothing we can do'. And they're walking out stronger — without ever seeing an OR (operating room). This isn't the future of valve care. It's happening now. Small clip. Big impact.' What is an open heart surgery? According to The National Heart, Lung, and Blood Institute (NHLBI), open heart surgery is a procedure where surgeons operate on the heart after making a large incision in the chest to access the heart and surrounding structures. It's typically used to address severe heart conditions like coronary artery disease, faulty valves, or congenital defects. During the surgery, a heart-lung bypass machine often maintains circulation while the heart is stopped to allow for repair. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Yahoo
17-07-2025
- Business
- Yahoo
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat
Abbott Laboratories ABT reported second-quarter 2025 adjusted earnings per share (EPS) of $1.26, which beat the Zacks Consensus Estimate by 0.8%. The figure improved 10.5% from the prior-year quarter's level. GAAP EPS was $1.01 compared with 74 cents in the second quarter of 2024. Following the earnings announcement, ABT stock fell 5% at pre-market trading today. The share price drop might be due to its reserved third-quarter guidance, which came in slightly below the Zacks Consensus Estimate. ABT's Q2 Revenues Worldwide sales of $11.14 billion were up 7.4% year over year on a reported basis. The top line surpassed the Zacks Consensus Estimate by 0.6%. Organically, sales improved 6.9% year over year. Organic sales, ex-COVID rose 7.5% year over year. ABT's Q2 Results in Detail Abbott operates through four segments — Established Pharmaceuticals, Medical Devices, Nutrition and Diagnostics. Established Pharmaceuticals' product sales increased 6.9% on a reported basis (7.7% on an organic basis) to $1.38 billion. Organic sales in key emerging markets improved 8.7% year over year. This was led by double-digit growth in several countries, including Asia, Latin America and the Middle East. In the second quarter, the Medical Devices segment's sales rose 13.4% year over year on a reported basis (12.2% organically) to $5.37 billion. Sales growth was led by Diabetes Care, Structural Heart and Heart Failure and Electrophysiology. Several products, including FreeStyle Libre, Navitor, TriClip, and AVEIR, contributed to the strong performance. The Diabetes Care division reported organic sales growth of 19.6% year over year, led by sales of continuous glucose monitors, which accounted for $1.90 billion of total sales. Structural Heart sales rose 11.7%, and Heart Failure sales improved 14% year over year organically. The Vascular division recorded organic sales growth of 3.5%. The Electrophysiology, Rhythm Management and Neuromodulation divisions recorded organic growth of 10.3%, 9.8% and 4.3%, respectively, in the quarter under review. For the second quarter, Nutrition sales rose 2.9% year over year on a reported basis (up 3.4% organically) to $2.21 billion. Pediatric Nutrition sales were up 0.2%, and Adult Nutrition sales improved 6.6% organically. According to the company, Adult Nutrition sales benefited from the strong global growth of Ensure and Glucerna, Abbott's market-leading brands. For the second quarter, Diagnostics sales declined 1% year over year on a reported basis (down 1.4% organically) to $2.17 billion. Organic sales, ex-COVID, rose 0.8%. Core Laboratory Diagnostics sales were up 1.6% organically. Molecular Diagnostics' sales declined 3.4% on an organic basis. Rapid Diagnostics sales were down 6.8%. Point of Care Diagnostics sales decreased 5.2%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Margin Details of ABT In the second quarter, the gross profit rose 8.9% year over year to $6.29 billion despite a 5.4% increase in the cost of products sold (excluding amortization expense). The gross margin expanded 79 basis points (bps) to 56.4%. Selling, general and administration expenses rose 5.3% year over year to $3.09 billion. Research and development expenses rose 3.9% year over year to $725 million. The company reported an adjusted operating profit of $2.47 billion, up 15.5% year over year. Also, the adjusted operating margin expanded 156 bps to 22.2%. ABT's 2025 Financial Guidance Abbott expects full-year adjusted diluted EPS to be in the range of $5.10-$5.20 (earlier $5.05-$5.25). The Zacks Consensus Estimate for the metric is pegged at $5.16. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote Full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, is expected to be in the range of 7.5-8.0%, or 6.0-7.0% when including COVID-19 testing-related sales. The Zacks Consensus Estimate for sales is currently pegged at $44.70 billion, suggesting a 6.6% improvement from the 2024 level. For the third quarter of 2025, adjusted diluted EPS is expected to be between $1.28 and $1.32. The Zacks Consensus Estimate for the metric is pegged at $1.34. Our Take Abbott exited the second quarter of 2025 with better-than-expected results. Both its earnings and revenues beat their respective estimates. Additionally, the figures improved on a year-over-year basis. All business segments experienced growth during the reported quarter, except Diagnostics. Meanwhile, Abbott's Diagnostics sales growth continued to be adversely impacted by year-over-year declines in COVID-19 testing-related sales, along with volume-based procurement programs in China. During the reported quarter, Abbott announced favorable data from the AVEIR Conduction System Pacing (CSP) clinical feasibility study. Additionally, the company received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR) system — a first-of-its-kind device to help treat people with mitral valve disease. Meanwhile, Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia, expected to be completed by 2028. In addition, the expansion of both margins is encouraging. ABT's Zacks Rank and Other Key Picks Abbott currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the broader medical space are Veeva Systems VEEV, Intuitive Surgical ISRG and Boston Scientific BSX. Veeva Systems, currently sporting a Zacks Rank #2, reported first-quarter fiscal 2026 adjusted EPS of $1.97, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $759 million beat the consensus mark by 4.3%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. VEEV has an estimated long-term earnings growth rate of 23.3% compared with the industry's 19.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 10%. Intuitive Surgical, carrying a Zacks Rank #2 at present, posted first-quarter 2025 adjusted EPS of $1.81, which exceeded the Zacks Consensus Estimate by 5.9%. Revenues of $2.25 billion surpassed the Zacks Consensus Estimate by 3.3%. ISRG has an estimated long-term earnings growth rate of 15.1% compared with the industry's 14.4%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.6%. Boston Scientific, carrying a Zacks Rank #2, reported a first-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 0.1%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 20.9%. BSX has a long-term earnings growth rate of 13.2% compared with the industry's 13.9%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Malaysian Reserve
04-06-2025
- Business
- Malaysian Reserve
MemorialCare Heart & Vascular Institute Completes First Successful TriClip Procedure for Tricuspid Valve Repair
LONG BEACH, Calif., June 4, 2025 /PRNewswire/ — The cardiology team at the MemorialCare Heart & Vascular Institute at Long Beach Medical Center, led by Chief of Cardiology David Shavelle, M.D., performed Long Beach Medical Center's first transcatheter tricuspid valve replacement procedure using a new, innovative treatment option – the transcatheter edge-to edge repair (TEER) TriClip G4 System in September of 2024. The FDA-approved TriClip is a small clipping device designed to clip two or more of the leaflets of the tricuspid, offering a minimally invasive treatment option to patients who have tricuspid regurgitation (TR) – a condition where the tricuspid valve does not close completely when the right ventricle contracts. This device – implanted via a catheter inserted in the vein of the leg – helps reduce tricuspid regurgitation and promotes an immediate improvement in blood flow and allows patients to benefit from a less traumatic procedure and a faster recovery. This advanced technology marks a new era for treating tricuspid valve disease since prior to its introduction, patients could only receive a device better suited for the mitral valve (MitraClip® device). The TriClip device was specifically made for the tricuspid valve. In a large clinical trial, the device was shown to reduce symptoms and hospitalization for heart failure for patients at high-risk for open-heart surgery. 'This new procedure represents a significant advancement in our ability to treat high-risk patients with tricuspid valve heart disease,' says Dr. Shavelle, who led the landmark procedure. 'Historically there wasn't much we could do for those who still had symptoms after tricuspid regurgitation treatment and who were at high-risk for open heart surgery. This device gives patients access to improved quality of life.' This procedure was performed by a highly skilled, diverse team of cardiologists, cardiac surgeons, cardiac anesthesiologists and advanced imaging specialists from the MemorialCare Heart & Vascular Institute at Long Beach Medical Center. Implantation of the TriClip with the TriClip G4 System is as effective as open-heart surgery, helping patients return to their daily lives in one to two days. 'The patient recovered in the hospital for about two days, and he was able to return to his daily life the following day,' says Dr. Shavelle. 'It's amazing to see the positive impact this device has on our patients, allowing them to return to their daily lives with improved heart function and overall well-being.' The patient who received this procedure, Anthony Williams, reported being fatigued constantly with excessive swelling of the legs (edema) before the procedure. Today, he is more energetic than ever and ready to take on each day. MemorialCare Heart & Vascular Institute at Long Beach Medical Center is the first institute in the region to use this device and continues to lead in cardiovascular innovations, bringing patients with the latest technology advancements. As one of the most high performing hospitals according to U.S. News, MemorialCare Long Beach Medical Center is a six-time five-star recipient recognized for its excellence in cardiac care by Healthgrades, and has recently received the American Heart Association's Get With The Guidelines® Heart Failure Gold Plus Quality Achievement Award, as well as the American Heart Association/American Stroke Association's Get With The Guidelines® Stroke Gold Plus Quality Achievement Award. With these achievements and offering a comprehensive range of services for patients with cardiac disorders, including rehabilitation programs, Long Beach Medical Center is a community hospital dedicated in providing expert and compassionate care on par with those found in academic settings. About MemorialCare Long Beach Medical Center: MemorialCare Long Beach Medical Center is a member of MemorialCare, a not-for-profit, integrated healthcare system. Long Beach Medical Center has been providing the community with compassionate, quality health care for more than 100 years. At the forefront of specialized care, research, and education, Long Beach Medical Center uses the most advanced healthcare technologies, including pioneering surgical systems like – ExactechGPS® and ExcelsiusGPS®. Recognized among the top 3% of all California acute care hospitals, Long Beach Medical Center is recognized as 'Best Hospital' for OBGYN and Orthopedics and ranked regionally in the Los Angeles Metro Area by U.S. News & World Report and earned Magnet® recognition for nursing excellence. With premier centers dedicated to cancer, heart, rehabilitation, orthopedics, neurosciences, and trauma, physicians and surrounding hospitals continually refer to its accredited programs. For more information, visit
Yahoo
04-06-2025
- Business
- Yahoo
MemorialCare Heart & Vascular Institute Completes First Successful TriClip Procedure for Tricuspid Valve Repair
LONG BEACH, Calif., June 4, 2025 /PRNewswire/ -- The cardiology team at the MemorialCare Heart & Vascular Institute at Long Beach Medical Center, led by Chief of Cardiology David Shavelle, M.D., performed Long Beach Medical Center's first transcatheter tricuspid valve replacement procedure using a new, innovative treatment option – the transcatheter edge-to edge repair (TEER) TriClip G4 System in September of 2024. The FDA-approved TriClip is a small clipping device designed to clip two or more of the leaflets of the tricuspid, offering a minimally invasive treatment option to patients who have tricuspid regurgitation (TR) – a condition where the tricuspid valve does not close completely when the right ventricle contracts. This device – implanted via a catheter inserted in the vein of the leg – helps reduce tricuspid regurgitation and promotes an immediate improvement in blood flow and allows patients to benefit from a less traumatic procedure and a faster recovery. This advanced technology marks a new era for treating tricuspid valve disease since prior to its introduction, patients could only receive a device better suited for the mitral valve (MitraClip® device). The TriClip device was specifically made for the tricuspid valve. In a large clinical trial, the device was shown to reduce symptoms and hospitalization for heart failure for patients at high-risk for open-heart surgery. "This new procedure represents a significant advancement in our ability to treat high-risk patients with tricuspid valve heart disease," says Dr. Shavelle, who led the landmark procedure. "Historically there wasn't much we could do for those who still had symptoms after tricuspid regurgitation treatment and who were at high-risk for open heart surgery. This device gives patients access to improved quality of life." This procedure was performed by a highly skilled, diverse team of cardiologists, cardiac surgeons, cardiac anesthesiologists and advanced imaging specialists from the MemorialCare Heart & Vascular Institute at Long Beach Medical Center. Implantation of the TriClip with the TriClip G4 System is as effective as open-heart surgery, helping patients return to their daily lives in one to two days. "The patient recovered in the hospital for about two days, and he was able to return to his daily life the following day," says Dr. Shavelle. "It's amazing to see the positive impact this device has on our patients, allowing them to return to their daily lives with improved heart function and overall well-being." The patient who received this procedure, Anthony Williams, reported being fatigued constantly with excessive swelling of the legs (edema) before the procedure. Today, he is more energetic than ever and ready to take on each day. MemorialCare Heart & Vascular Institute at Long Beach Medical Center is the first institute in the region to use this device and continues to lead in cardiovascular innovations, bringing patients with the latest technology advancements. As one of the most high performing hospitals according to U.S. News, MemorialCare Long Beach Medical Center is a six-time five-star recipient recognized for its excellence in cardiac care by Healthgrades, and has recently received the American Heart Association's Get With The Guidelines® Heart Failure Gold Plus Quality Achievement Award, as well as the American Heart Association/American Stroke Association's Get With The Guidelines® Stroke Gold Plus Quality Achievement Award. With these achievements and offering a comprehensive range of services for patients with cardiac disorders, including rehabilitation programs, Long Beach Medical Center is a community hospital dedicated in providing expert and compassionate care on par with those found in academic settings. About MemorialCare Long Beach Medical Center: MemorialCare Long Beach Medical Center is a member of MemorialCare, a not-for-profit, integrated healthcare system. Long Beach Medical Center has been providing the community with compassionate, quality health care for more than 100 years. At the forefront of specialized care, research, and education, Long Beach Medical Center uses the most advanced healthcare technologies, including pioneering surgical systems like – ExactechGPS® and ExcelsiusGPS®. Recognized among the top 3% of all California acute care hospitals, Long Beach Medical Center is recognized as "Best Hospital" for OBGYN and Orthopedics and ranked regionally in the Los Angeles Metro Area by U.S. News & World Report and earned Magnet® recognition for nursing excellence. With premier centers dedicated to cancer, heart, rehabilitation, orthopedics, neurosciences, and trauma, physicians and surrounding hospitals continually refer to its accredited programs. For more information, visit View original content to download multimedia: SOURCE MemorialCare Long Beach Medical Center
Yahoo
29-05-2025
- Business
- Yahoo
Abbott Stock Gains Following FDA Approval of the Tendyne System
Abbott Laboratories ABT has recently received Food and Drug Administration ('FDA') approval for its Tendyne transcatheter mitral valve replacement ('TMVR') system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification ('MAC'). The Tendyne system expands the company's comprehensive Structural Heart portfolio. After the announcement, Abbott shares edged up 1.3%, finishing at $132.94 yesterday. The company's Structural Heart arm benefits from a unique range of product portfolio, which includes MitraClip, a mitral valve transcatheter edge-to-edge repair system, and TriClip, a tricuspid valve transcatheter edge-to-edge repair system. The portfolio also contains transcatheter aortic heart valves — Portico and Navitor. Hence, we expect the market sentiment toward ABT stock to remain positive surrounding the latest development. Abbott holds a market capitalization of $231.29 billion. The company's earnings yield of 3.9% surpasses the industry's 0.6%. ABT delivered an average earnings beat of 1.6% in the trailing four quarters. MAC stiffens the structure of the mitral valve and can lead to mitral regurgitation or stenosis that disrupts the heart's ability to pump blood effectively. The complex nature of this mitral valve disease and patients' specific needs and health conditions can pose challenges for surgical correction. The Tendyne system offers an alternative, minimally invasive way to replace the valve of patients with severe MAC who are at high risk for open-heart surgery. The innovative and unique design of the Tendyne system and the valve's availability in multiple sizes allow it to adapt to a range of patient anatomies. The self-expanding valve is delivered through a small incision in the chest and then advanced into the heart to replace the mitral valve. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people requiring a valve replacement. Image Source: Zacks Investment Research Per Medi-Tech Insights' report, the TMVR market is projected to witness a compound annual growth rate of 20% from 2025 to 2030. Key factors driving growth are increased prevalence of mitral valve diseases, growing preferences for minimally invasive procedures and expanding geriatric population. Earlier this month, Abbott unveiled results from its REFLECT real-world studies, conducted using data from the comprehensive Swedish National Diabetes Register. The findings revealed that the company's FreeStyle Libre continuous glucose monitoring (CGM) technology helps significantly reduce the risk of hospitalization for heart complications in people with diabetes. Over the past year, Abbott's shares have risen 32%, surpassing the industry's 10.3% growth. Abbott currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, AngioDynamics ANGO and STERIS STE. PAHC carries a Zacks Rank #1 (Strong Buy) at present. It has an estimated long-term earnings growth rate of 26.2% compared with the industry's 15.9%. You can see the complete list of today's Zacks #1 Rank stocks here. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 30.6%. Its shares have rallied 26.3% compared with the industry's 10% growth in the past year. AngioDynamics, carrying a Zacks Rank #1 at present, has an estimated earnings growth rate of 23.7% for 2025. ANGO's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 70.85%. ANGO's shares have risen 49.2% in the past year compared with the industry's 5.5% growth. STERIS, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 10.8% for 2025. STE's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.61%. Its shares have risen 34.1% compared with the industry's 7.7% growth in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
